Acceptance Rates for Pharmacist-Initiated Interventions in Long-Term Care Facilities by Carson, Gina L. et al.
Volume 4 | Number 4 Article 135
2013
Acceptance Rates for Pharmacist-Initiated
Interventions in Long-Term Care Facilities
Gina L. Carson
Kimberly Crosby
Garrett R. Huxall
Nancy C. Brahm
Follow this and additional works at: http://pubs.lib.umn.edu/innovations
INNOVATIONS in pharmacy is published by the University of Minnesota Libraries Publishing.
Recommended Citation
Carson GL, Crosby K, Huxall GR, Brahm NC. Acceptance Rates for Pharmacist-Initiated Interventions in Long-Term Care Facilities.
Inov Pharm. 2013;4(4): Article 135. http://pubs.lib.umn.edu/innovations/vol4/iss4/6
Original Research PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                      2013, Vol. 4, No. 4, Article 135                          INNOVATIONS in pharmacy   1 
 
Acceptance Rates for Pharmacist-Initiated Interventions in Long-Term Care Facilities  
Gina L. Carson, PharmD; Kimberly Crosby, PharmD, BCPS, CDE, BC-ADM; Garrett R. Huxall, PharmD, CGP;  and Nancy C. Brahm, 
PharmD, MS, BCPP, CGP 
The University of Oklahoma College of Pharmacy 
 
Key Words: consulting pharmacist, consultant pharmacist, long term care, nursing homes, pharmacist intervention 
 
 
Abstract 
Objectives: Describe individualized medication interventions, categorize intervention types, and report acceptance rates by 
prescribers following a pilot medication intervention program in which a pharmacist rounded with the patient care team in long-term 
care facilities in addition to their traditional medication regimen review (MRR) process.  
Design: Prospective Chart review  
Setting: Two primary long-term care (LTC) facilities  
Participants: Fifty randomly selected patient charts. Inclusion criteria were adult patients (18 years old or older) residing in one of the 
LTC facilities receiving consultant pharmacist services. Patient charts not meeting inclusion criteria were excluded from the review.  
Interventions: Recommendations made according to the needs of each patient and categorically reported.  
Main Outcome Measures: Intervention acceptance rates by prescribers and aggregate reporting for type of medication 
interventions. 
Results: For 50 patient charts (68% female, 32% male) 66 interventions were reported. The average patient age was 81.5 years. 
Approximately 45% of the interventions pertained to drug utilization concerns, and 21% involved pain management. Additional 
categories included treatment of eye and skin conditions and pharmacotherapy for mental health. A ‘nonpharmacotherapy’ 
designation was given to individual interventions not fitting into a larger category. New medications and regimen changes were the 
most common medication therapy outcomes (42% and 32%, respectively). Overall 92% of all pharmacist interventions were either 
fully or partially accepted by the prescriber where partial acceptance was defined as implementation of the recommendation with an 
adjustment. Interventions related to drug utilization or pain management each approached a 93% acceptance rate.  
Conclusions: The consultant pharmacist provided personalized recommendations following extensive chart review and patient 
assessment. Our chart review suggests that high prescriber acceptance rates along with medication therapy optimization may 
produce similar benefits in other LTC facilities.  
 
 
Introduction 
Two-thirds or 32% of Medicare beneficiaries have two or 
more chronic conditions; 23% have four to five chronic 
conditions, and 14% have six or more according to 2010 data 
from the Centers for Medicare and Medicaid Services.
1
 
Maintaining adequate control of chronic medical conditions 
by evaluating the therapeutic outcome is of value in the long 
term care (LTC) setting. Chronic disease states with specific 
clinical practice guidelines, including diabetes, hypertension, 
and stroke, are highlighted in a recent study as common 
diagnoses among LTC patients.
2
 Adherence to these 
guidelines is extremely important for managing these 
diseases. Patients receiving disease state management 
services by pharmacists are four to seven times more likely to  
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be within clinical practice guideline recommendations 
compared to those who did not receive pharmacist-driven 
services.
2
  
 
With age, changes in protein binding, renal and hepatic 
functions, drug metabolism and excretion, and drug 
distribution increase the potential for adverse drug reactions 
(ADRs),  defined as unintended responses to a drug and toxic 
effects of certain drugs.
3
 Increased longevity also increases 
the potential for unnecessary drug exposure unless the 
medication regimen is evaluated to determine if more 
effective pharmacotherapy could be implemented.
4
 
Inappropriate medication therapies can lead to increased 
healthcare costs including more emergency department (ED) 
visits from ADRs and hospitalizations due to inappropriate 
care.
5
 Pharmacists can play an active role detecting problems 
and recommending appropriate use of medications, 
particularly with polypharmacy in the elderly. 
 
One study suggested that a medication review by a 
pharmacist resulted in a reduction in the number of 
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prescribed medications to nursing home patients. These 
findings reinforce the value of implementation of th is  
simple, low-cost intervention. In addition, pharmacist 
medication review had the potential to decrease costs.
6
 
Studies which measure the impact of pharmacists’ 
medication therapy recommendations in nursing home 
residents have shown mixed results. Often both consultant 
and onsite pharmacist services  may be provided making it 
difficult to measure outcomes from one of these services 
specifically, and often studies which align mediation 
recommendation changes to decreases in falls or morbidity 
and mortality have shown no difference or limited 
differences. Increasingly evidence supports involvement of a 
pharmacist increases knowledge and awareness of 
medication-related issues for other healthcare professionals.
7
 
The value of the pharmacist medication review and inclusion 
as a member of an interdisciplinary care team has been 
recognized as improving prescribing and potentially 
decreasing costs.
8,9
 Age-related changes and the positive 
impact of the pharmacist as a member of the interdisciplinary 
team have been recognized in a variety of settings as well. In 
an acute care geriatric unit, the addition of a clinical 
pharmacist resulted in 76 interventions in a 3-month period. 
Interventions covered areas of pharmacotherapy that 
included identified as drug selection, dosing, changes in 
therapy, and medication reconciliation.
10
  
 
This chart review evaluates the outcomes associated with a 
pilot medication intervention program in which the 
pharmacist rounded with the physician and other members 
of the patient care team as a step in the completion of the 
medication regimen review (MRR). We describe the types of 
interventions identified, how these were resolved, and 
acceptance rates by prescribers at two primary care LTC 
facilities.  
 
Methods 
Study Design 
Before initiation of the pilot medication intervention 
program, pharmacist services provided routinely in the long-
term care (LTC) facility included medication regimen review 
(MRR) which consisted of identifying drug-drug interactions, 
dosing appropriateness, medication reconciliation to ensure 
that the medication administration record (MAR) matched 
current physician orders, and making recommendations for 
laboratory tests needed to monitor medication therapy. Any 
medication-therapy recommendations were communicated 
to the LTC physician by chart note. The pharmacists did not 
communicate directly with providers or patients as a part of 
their services. This new pilot medication intervention 
program combined the traditional MRR process with 
rounding activities as a member of the patient care team 
during which patient-focused discussions with healthcare 
providers and interviews with nursing home patients would 
occur. If the pharmacist was not able to be present during 
this patient interview, he/she followed up with the patient at 
the first available opportunity. The patient care team was 
interdisciplinary and included physician, nursing, and any 
allied healthcare professionals working with the patient. The 
pharmacists rounded using a standardized intervention form 
that identified current patient problems or concerns and/or 
medication-related issues. Pharmacist recommendations for 
resolution of these issues were included on the form. The 
pharmacist would present the medication-related issues to 
the team during the rounding process. Clinical interventions 
included, but were not limited to, addressing reports of 
current ailments, any difficulties taking medication (i.e., 
tablet size or dosage form), and/or adverse effects related to 
current medication therapy. In addition, persons providing 
patient care were queried on any changes in the environment 
or other patient-specific variables that may have occurred 
since the team last rounded.  
 
The chart review was conducted on 50 randomly selected 
patient charts of persons residing in two LTC facilities 
receiving contract clinical pharmacist consulting services in 
which this pilot medication intervention program was being 
implemented. Charts were reviewed by a pharmacy intern-
researcher to collect, analyze, and categorize data about 
types of interventions, acceptance rates, and categories of 
pharmacist-initiated intervention recommendations using a 
data collection form. Intervention acceptance rates were 
categorized as accepted, partially accepted, or not accepted. 
Interventions were classified by type of patient problem 
addressed. After identification, interventions related to 
medications were identified as starting a new medication, 
changing existing medication, discontinuing a medication, or 
no change in medication therapy. Approval from the 
Institutional Review Board (IRB) was obtained for this project.  
 
For the purposes of this chart review, an intervention was 
defined as any recommendation given by the pharmacist to 
alleviate a patient problem identified during interdisciplinary 
collaboration. An example would be recommending 
reduction of a resident’s medication dose due to a recent fall 
or initiation of an antidepressant for a resident that reported 
crying daily (ruling out pain as a contributing factor). 
Interventions were submitted to the prescriber for review as 
either a chart note or during the interdisciplinary meeting. 
Either a chart note from the physician or a response on the 
intervention form was used to determine the acceptance of 
the pharmacist intervention. If the intervention was not 
accepted, the prescriber documented his/her rationale. An 
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alternative plan to address the problem may or may not have 
been included by the physician on the intervention form.  
 
Statistical Analysis 
A database was created with categorical information for 
analysis that included patient date of birth, age, ethnicity, 
gender, disease states, reported problem(s), medication 
therapy interventions, and intervention acceptance. 
Statistical methods included nominal and aggregate 
reporting.  
 
Results 
Patient Demographics 
The patient demographics of the charts reviewed (n=50) are 
described in Table 1. The most common disease states 
represented during the chart reviews were hypertension, 
dementia, depression, gastroesophageal reflux disease 
(GERD), and pain.  
 
Intervention Characteristics 
Among the 50 patient charts reviewed, 66 interventions were 
made. Interventions were divided into five categories 
according to the type of patient problem identified. These 
categories included [1] drug utilization, [2] pain management, 
[3] nurse or patient administered treatment of eye or skin 
conditions, [4] pharmacotherapy for mental health, and [5] 
nonpharmacotherapy for interventions that did not fit into a 
larger category. The drug utilization category interventions 
included addressing subtherapeutic or supratherapeutic 
doses, unnecessary medications, unwanted side effects, and 
drug-drug interactions. Pharmacist recommendations 
targeting these patient-specific areas, the degree to which 
these recommendations were accepted, and resolution of 
these problems were the foci of our chart review. Table 2 
summarizes the results.  
 
Interventions addressing drug utilization represented the 
most common type in this chart review. Approximately 45% 
of the total interventions (n=66) were related to drug 
utilization. Pain management was addressed in 21% of the 
pharmacist interventions. Pain management problems 
identified included uncontrolled pain in specific areas of the 
body (i.e., joint, back, nerve, and headache) as well as 
generalized pain. Inadequate pain control was reported in 14 
patient charts. Recommendations for eye or skin related 
conditions represented 12% of the interventions made. 
Depression, dementia, and aggressive behaviors reported in 
the absence of pharmacotherapy represented the 
pharmacotherapy for mental health interventions. These 
interventions were made in five patient charts (8% of total 
interventions). The ‘nonpharmacotherapy’ interventions 
contained concerns unrelated to any of the previous 
categories (i.e., sinus congestion, excessive salivation, or dry 
mouth) and represented 14% of the interventions made.  
Medication-Related Problem Resolution Categories 
 
Interventions resulted in four different medication problem 
resolution categories. These included [1] new medication 
initiation, [2] existing medication discontinuation, [3] current 
medication dose or regimen adjustment, and [4] reviews 
without changes. Results are summarized in Table 3. Forty-
two percent of all interventions involved initiating a new 
medication to resolve patient-specific concern(s). The second 
most common category was existing medication 
discontinuation, representing 32% of the interventions. This 
was followed by current medication dose or regimen 
adjustment, and reviews without changes (17% and 9%, 
respectively).  
 
Special attention was given to the addition of 
pharmacotherapy to an existing regimen. Recommendations 
for medication changes and interventions consistently sought 
to identify medication(s) and medication classes with the 
potential for severe adverse effects and negative outcomes in 
older adults.
11
 Examples included the recommendation to 
add a stimulant laxative to the resident’s medications after a 
routine narcotic for pain management was ordered by the 
primary care provider. Specific to this pilot medication 
intervention program was an in-depth review of the bowel 
and bladder protocols for patients on opioids or regimens 
associated with constipation, and any changes that were 
documented after pharmacist-initiated patient-specific 
recommendations. In addition, if residents were requesting 
an ‘as needed’ analgesic ordered on a routine basis, these 
were addressed with a dosage adjustment, keeping the ‘as 
needed’ orders in case of breakthrough pain.  
 
Intervention Acceptance 
Intervention acceptance was categorized as accepted, 
partially accepted, or not accepted by the prescriber. If the 
pharmacist’s recommendation was implemented exactly as 
written on the intervention form, it was considered accepted. 
Partial acceptance was defined as implementation of the 
pharmacist’s recommendation with a minor change. For 
example, if the pharmacist recommended a gabapentin dose 
increase with a specific dose and administration schedule. 
The prescriber partially accepted this recommendation by 
accepting the schedule but increased the dosing beyond the 
recommendation. If the prescriber disagreed with the 
pharmacist’s recommendation, the intervention was 
considered ‘not accepted.’ For these charts, the prescriber 
either documented an alternative plan of action or no change 
in current therapy was made. Tables 4 and 5 summarize the 
results.  
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There was an acceptance rate of 92% for full or partial 
acceptance of pharmacist interventions by prescribers in this 
chart review: 88% accepted, 4% partially accepted. Only 8% 
of the interventions were not accepted. Among the drug 
utilization and pain management categories 93% of the 
recommendations were accepted. Approximately 88% of the 
‘nonpharmacotherapy’ interventions and 89% of the nurse or 
patient administered treatment of eye or skin conditions 
interventions were accepted. One hundred percent of the 
pharmacotherapy for mental health interventions was 
accepted by prescribers.  
 
Discussion 
Our medication intervention program is unique in that it 
exceeded all state and federal requirements for monitoring 
and adds a focus on individualized interventions. Support for 
individualized patient-focused interventions was 
recommended by Clark et al. who advocated moving the MRR 
to a more focused approach with occasional visits to the 
patients.
12,13
 This pilot medication intervention program was 
undertaken to provide individualized patient 
recommendations based on the medication regimen matched 
to the activities of daily living, functional status, and patient-
specific information. Specific patient concerns were 
addressed at each visit, and focused information targeting a 
specific area of concern was addressed. If the clinical 
pharmacist was not available, other healthcare professionals 
gathered the information for pharmacist review and follow-
up.  
 
This chart review provided valuable information about 
pharmacist interventions in LTC facilities. The results 
suggested the pilot medication intervention in which 
consultant pharmacists had multi modal approach towards 
MRR had a positive impact in the LTC setting. This was 
evidenced by the changes made to the medication therapy 
regimens and the high prescriber acceptance rate of the 
pharmacist’s recommendations. The consultant pharmacist 
focused on each patient in addition to monitoring medication 
usage facility-wide.  
 
With drug utilization and pain management issues being the 
most common in this LTC setting, it was valuable that the 
pharmacist was able to optimize patient medication therapy 
regimens. Pharmacist-initiated changes resolved unwanted 
side effects, eliminated unnecessary medications, reduced 
drug-drug interactions, corrected dosing, and managed pain 
more effectively. How these recommendations, if 
implemented, changed these patient outcomes, with 
longitudinal follow-up with these patient charts, is an area for 
further investigation, particularly with respect to incidences 
of ADRs or adverse drug events (ADEs) and therapeutic 
outcomes.  
 
The potential for untoward drug use consequences was 
considered with each recommendation. ADRs are unintended 
responses to a drug that are toxic occurring at normal 
therapeutic doses, whereas ADEs are any injury resulting 
from the use of a drug which includes ADRs, overdoses, and 
any other harm from the use of the drug.
3
 One study of 
geriatric outpatients who had received a pharmacist 
medication consult found when comparing ADRs at baseline 
and at 2 months, ADRs originally reported at baseline 
decreased in the intervention group compared to the control 
group.
14
 Another study reported that 30% of patients 
receiving a pharmacist intervention reported ADEs compared 
to 42% in the control group, although this was not statistically 
significant.
15
 The review article that looked at medication 
reconciliation in the transfer of patients from outpatient 
settings to LTC settings stated that preventable ADEs at 
transition points accounted for approximately 50% of all 
medication errors. These events, ADEs and ADRs, were 
associated with frequent ED visits and hospitalizations, 
leading to increased healthcare costs.
16-18
 In transitions to LTC 
settings, pharmacists may be a cost-effective way to address 
costs and improve patient outcomes.  
 
Our acceptance rate of 92% is comparable to physician 
acceptance in other settings.
19,20
 This suggests that 
pharmacists can have the same impact in LTC facilities as in 
outpatient clinical settings. The high acceptance rate in our 
study implies that pharmacists are trusted by prescribers to 
make appropriate decisions regarding drug therapy which 
could also translate to a savings in healthcare costs. The 
majority of medication outcomes resulted in starting a new 
medication or changing the dose of a current medication to 
resolve a patient-specific concern. In the absence of a 
pharmacist, a patient would be required to make an 
appointment with a prescriber to reconcile this issue. 
Pharmacists may be able to reduce costs by working in 
conjunction with prescribers to enhance medication therapy 
management. In addition, discontinuing a medication due to 
an ADE or lack of indication would not only result in direct 
savings, but it may also reduce the need for hospitalizations 
due to ADRs and ADEs.  
 
Limitations 
This chart review had several limitations. The first was a small 
sample size. With only 50 patient charts from two different 
facilities, the results cannot be generalized to the entire 
patient population in the LTC. Secondly, not all information 
may have been recorded in the chart or on the intervention 
form and, if not present for interactions, was dependent on 
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charted information. Reporting may have been variable 
depending on who recorded the patient information (i.e., 
pharmacist, physician, nursing staff, or allied healthcare 
professional). The potential for bias is acknowledged.  
 
Conclusion 
Traditional activities of the consulting pharmacist (whereby 
the consultant reviews the patient’s chart, verifies the lab 
results, performs any dosage adjustment calculations needed, 
and ensures correct transcription of the medication regimen 
to the medication administration record) can be carried out 
without direct patient or healthcare team contact. This 
medication intervention program initiative included 
introduction of a standardized intervention form, direct 
contact with the team (particularly rounding with the team), 
and whenever possible, hearing patient concern(s), and 
discussing findings with the prescriber. Direct pharmacist-
prescriber contact provided an opportunity to demonstrate 
the value of the pharmacist as a team member for patient-
centered care and work one-on-one with the prescriber.  
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Table 1: Patient Demographics 
 
Variable Representation in Sample 
Gender Female: 68% 
Male: 32% 
Age Range: 59 to 97 years of age 
Mean: 81.5 years 
Caucasian 84% 
African-American 6% 
Hispanic 2% 
American Indian 8% 
 
 
 
Table 2: Types of Pharmacist Interventions 
 
Intervention Type Number of Interventions (%) 
Drug Utilization* 30 (45) 
Pain Management 14 (21) 
Nurse or Patient Administered Treatment of Eye or Skin 
Conditions 
8 (12) 
Pharmacotherapy for Mental Health 5 (8) 
Nonpharmacotherapy 
Dislikes taste of crushed medication (2) 
Dry mouth (2) 
Excessive saliva (1) 
Medication too large to swallow comfortably (1) 
Sinus congestion (1) 
Unable to reach water (1) 
Unable to see television (1) 
9 (14) 
Total 66 (100) 
*The drug utilization category includes drug use evaluation, medication use evaluation, and medication use management 
addressing subtherapeutic or supratherapeutic doses, unnecessary medications, unwanted side effects, and drug-drug 
interactions.  
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Table 3: Types of Problem Resolutions 
 
Problem Resolution Categories Number of Interventions (%) 
New medication initiation 28 (42) 
Existing medication discontinuation 21 (32) 
Current medication dose or regimen adjustment 11 (17) 
Reviews without changes 6 (9) 
Total 66 (100) 
 
 
 
Table 4: Intervention Acceptance 
 
Intervention Acceptance Number of Interventions (%) 
Accepted 58 (88) 
Partially Accepted 3 (4) 
Not Accepted 5 (8) 
Total 66 (100) 
 
 
 
Table 5: Intervention Acceptance by Type 
 
Intervention Type 
Number of Interventions 
Full Acceptance (%) Partial Acceptance (%) Not Accepted (%) 
Drug Utilization 27/30 (90) 1/30 (3) 2/30 (7) 
Pain Management 13/14 (93) 0/14 (0) 1/14 (7) 
Nurse or Patient Administered 
Treatment of Eye or Skin 
Conditions 
5/8 (63) 2/8 (25) 1/8 (12) 
Pharmacotherapy for Mental 
Health 
5/5 (100) 0/5 (0) 0/5 (0) 
Nonpharmacotherapy 8/9 (89) 0/9 (0) 1/9 (11) 
Total 58/66 (88) 3/66 (4) 5/66 (8) 
 
 
